Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  DexCom, Inc.    DXCM

DEXCOM, INC.

(DXCM)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/14/2020 02/18/2020 02/19/2020 02/20/2020 02/21/2020 Date
283.91(c) 296(c) 291.68(c) 302.51(c) 291.25(c) Last
3 359 630 1 743 433 1 493 352 2 169 261 1 383 831 Volume
+12.57% +4.26% -1.46% +3.71% -3.72% Change
More quotes
Financials (USD)
Sales 2020 1 782 M
EBIT 2020 237 M
Net income 2020 182 M
Finance 2020 37,7 M
Yield 2020 -
Sales 2021 2 177 M
EBIT 2021 343 M
Net income 2021 269 M
Finance 2021 294 M
Yield 2021 -
P/E ratio 2020 156x
P/E ratio 2021 106x
EV / Sales2020 14,9x
EV / Sales2021 12,1x
Capitalization 26 677 M
More Financials
Company
Dexcom, Inc. (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company's products consist of DexCom G4... 
More about the company
Surperformance© ratings of DexCom, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on DEXCOM, INC.
02/20DEXCOM : G6 Continuous Glucose Monitoring (CGM) System Receives CE Mark for Use ..
BU
02/17DEXCOM : G6® CGM System Now Available In Canada
AQ
02/17DEXCOM : and Companion Medical Announce Collaboration to Integrate Dexcom CGM Da..
AQ
02/17DEXCOM : Announces FDA Clearance of New Dexcom G6 Pro CGM
AQ
02/13DEXCOM : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS..
AQ
02/13DEXCOM : 4Q Earnings Snapshot
AQ
02/13DEXCOM INC : Results of Operations and Financial Condition, Financial Statements..
AQ
02/13DEXCOM : Reports Fourth Quarter and Fiscal Year 2019 Financial Results
BU
02/10DEXCOM, INC. : annual earnings release
01/21DEXCOM SCHEDULES FOURTH QUARTER AND : 30 p.m. Eastern Time
BU
01/13DEXCOM INC : Results of Operations and Financial Condition, Financial Statements..
AQ
01/13DEXCOM : Reports Record Preliminary, Unaudited Revenue for the Fourth Quarter an..
BU
01/06DEXCOM : to Present at 38th Annual J.P. Morgan Healthcare Conference
BU
2019ELI LILLY AND COMPANY : - Lilly to Integrate Dexcom CGM into Personalized Diabet..
AQ
2019ELI LILLY AND : to Use Dexcom's Continuous Glucose Monitoring Devices
DJ
More news
News in other languages on DEXCOM, INC.
02/10DEXCOM, INC. : publication des résultats annuels
02/10DEXCOM, INC. : Veröffentlichung des Jahresergebnisses
2013DEXCOM, INC. : publication des résultats trimestriels
2012DEXCOM, INC. : publication des résultats trimestriels
More news
Analyst Recommendations on DEXCOM, INC.
More recommendations
Sector news : Medical Equipment, Supplies & Distribution - NEC
11:41aPharmaceutical companies develop system to better track counterfeit drugs
RE
02/20FISHER & PAYKEL HEALTHCARE : F&P Healthcare Raises Fiscal Year Earnings, Revenue..
DJ
02/20SMITH & NEPHEW : +Nephew forecasts sales growth after best year since 2010
RE
02/18MEDTRONIC : Raises 2020 Guidance, Sets 4Q Outlook
DJ
02/18MEDTRONIC : 3Q Profit, Sales Rise
DJ
More sector news : Medical Equipment, Supplies & Distribution - NEC
Chart DEXCOM, INC.
Duration : Period :
DexCom, Inc. Technical Analysis Chart | DXCM | US2521311074 | MarketScreener
Technical analysis trends DEXCOM, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 20
Average target price 289,28  $
Last Close Price 291,25  $
Spread / Highest target 8,50%
Spread / Average Target -0,68%
Spread / Lowest Target -36,5%
EPS Revisions
Managers
NameTitle
Kevin Ronald Sayer Chairman, President & Chief Executive Officer
Quentin S. Blackford Chief Operating & Financial Officer
Andrew K. Balo EVP-Clinical, Regulatory Affairs & Quality
Jacob Leach Chief Technology Officer
Jay S. Skyler Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
DEXCOM, INC.33.15%27 708
MEDTRONIC PLC0.28%152 662
BAXTER INTERNATIONAL INC.11.29%47 512
HOYA CORPORATION-0.10%34 262
ZIMMER BIOMET HOLDINGS5.82%32 578
TERUMO CORPORATION-1.33%25 818